Compare Genuine Parts Company (GPC) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs GSK plc — how do they compare? Genuine Parts Company trades at $126.93 (market cap $17.67B), while GSK plc trades at $46.65 (market cap $91.88B). The key difference: GSK plc is far larger — about 5.2× Genuine Parts Company's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and GSK plc for 93 Days on average.
| GPC | GSK | |
|---|---|---|
Market Cap | $17.67B | $91.88B |
Volume | 1,079,458 | 7,730,529 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $61.18 |
52-Week Low | $92.47 | $43.24 |
Typical Hold Time | 75 Days | 93 Days |
Enterprise Value | $23.76B | $111.88B |
Dividend Yield | 3.32% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $125.41, down 1.55% on the day, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $2.15, beating expectations, but net income margin remains thin at 0.13%. Analyst consensus is mixed with 43% buy ratings and a $145.75 price target. The planned Q1 2027 separation of automotive and industrial businesses represents a key catalyst, though profitability concerns persist amid declining cash flow trends.
The outlook remains cautious with near-term pressure from weak technicals and margin compression, balanced by potential upside from the corporate split. Key risks include execution of the separation, competitive pressures in auto parts distribution, and macroeconomic sensitivity. The stock offers value at current levels for investors betting on successful restructuring, but requires careful monitoring of Q3 earnings due October 20, 2026.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
